This interview provides perspective on developments in breast cancer treatment in 2017, as well as a preview of what we can expect to change in the treatment of breast cancer in 2018.
Oncology Vol 31 No 12_Suppl_1
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
